BioCryst Pharmaceuticals, Inc.BCRXNASDAQ

Revenue (LTM)

$875M

+94.1% YoY

Net Income (LTM)

$264M

+396.9% YoY

Free Cash Flow

$327M

Revenue CAGR (5Y)

+53.6%

—Marginsstable

FCFTurned positive

Now profitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	157	271↑72.3%	331↑22.4%	451↑36.0%	875↑94.1%
Gross Profit	150	264↑76.3%	327↑23.7%	438↑34.1%	856↑95.3%
Operating Income	-178	-148↑16.5%	-104↑30.1%	-3↑97.5%	341↑13508.9%
Net Income	-184	-247↓34.3%	-227↑8.3%	-89↑60.8%	264↑396.9%
EBITDA	-122	-144↓18.2%	-116↑19.1%	13↑111.0%	348↑2614.3%
EPS Diluted	-1.03	-1.33↓29.1%	-1.18↑11.3%	-0.43↑63.6%	1.21↑381.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	504	305↓39.6%	111↓63.7%	105↓5.2%	90↓14.5%
Total Current Assets	566	517↓8.8%	496↓4.0%	422↓14.9%	404↓4.2%
Total Assets	588	550↓6.5%	517↓6.0%	490↓5.1%	514↑4.8%
Total Current Liabilities	104	106↑1.7%	150↑42.1%	160↑6.9%	196↑22.2%
Total Liabilities	695	845↑21.5%	972↑15.1%	966↓0.6%	633↓34.5%
Total Equity	-107	-295↓175.4%	-456↓54.6%	-476↓4.5%	-119↑75.0%
Total Debt	593	741↑25.0%	825↑11.3%	841↑2.0%	477↓43.3%
Net Debt	89	437↑391.5%	715↑63.6%	736↑3.1%	388↓47.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-142	-162↓13.9%	-95↑41.2%	-52↑45.3%	330↑734.1%
Capital Expenditure	-2	-1↑43.4%	-2↓60.5%	-1↑48.2%	-2↓119.6%
Free Cash Flow	-145	-163↓12.9%	-97↑40.4%	-53↑45.4%	327↑716.1%
Stock-Based Comp	35	45↑29.0%	56↑24.4%	65↑17.6%	0
Net Change in Cash	233	-201↓186.3%	-194↑3.8%	-6↑96.8%	-103↓1587.2%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance